Tevogen (TVGN) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Veru (VERU) has outperformed Tevogen (TVGN) over the past year, losing 45.1% versus a loss of 80.5%. Tevogen is the larger company by market cap ($46.0 million vs $41.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TVGN | VERU |
|---|---|---|
| Share price | $7.06 | $2.42 |
| Market cap | $45.97M | $41.26M |
| 1-day change | +8.78% | -1.63% |
| YTD return | -57.34% | +13.08% |
| 1-year return | -80.50% | -45.12% |
| 5-year return | — | -97.18% |
| EPS (TTM) | $-6.74 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.00 | $7.33 |
| 52-week low | $3.64 | $2.05 |
| Distance from 52-week high | -81.90% | -66.98% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +960.74% |
| Average volume | 10.03K | 242.06K |
| Shares outstanding | 6.51M | 17.05M |
| Employees | 18 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERU has outperformed TVGN by 35.4 percentage points over the past year.
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Healthcare · Biotechnology · 18 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Healthcare · Biotechnology · 20 employees
TVGN vs VERU FAQ
Which is bigger, Tevogen or Veru?
Tevogen (TVGN) is larger, with a market capitalization of $45.97M compared with $41.26M for Veru (VERU).
Which stock has performed better over the past year, TVGN or VERU?
VERU returned -45.12% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Tevogen and Veru in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.